Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Lumen Technologies Inc (LUMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Lumen Technologies Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.63 (market cap $6.04B), while Lumen Technologies Inc trades at $5.29 (market cap $5.73B). The key difference: Iovance Biotherapeutics Inc. Common Stock and Lumen Technologies Inc are close in size by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Lumen Technologies Inc for 40 Days on average.
| IOVA | LUMN | |
|---|---|---|
Market Cap | $6.04B | $5.73B |
Volume | 14,805,993 | 17,079,799 |
Sector | Health | Media |
52-Week High | $14.82 | $11.83 |
52-Week Low | $1.81 | $5.53 |
Typical Hold Time | 0 Days | 40 Days |
Enterprise Value | $5.97B | $17.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lumen Technologies (LUMN) trades at $5.28, down 10.66% in the last session, reflecting ongoing investor concerns. The stock shows bearish technical signals with mixed earnings performance - beating estimates in Q4 2025 and Q2 2026 but missing in Q1 2026. Despite revenue declining from $17.5B in 2022 to $12.4B in 2025, the company maintains strong operating cash flow of $4.7B and is strategically pivoting toward AI networking services.
LUMN presents a high-risk turnaround opportunity with significant debt burden ($17.5B long-term) and negative profitability metrics. The AI-focused strategy shows promise but faces execution risk against steep legacy revenue declines. Analyst consensus remains cautious with 61% hold ratings, suggesting investors await concrete evidence of sustainable growth before committing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →
